25.07.2014 • NewsDede WillamsMerckMerck Serono

Merck Serono Extends Italian Alliance for Neurodegenerative Diseases

Merck Serono, the biopharmaceuticals arm of Germany's Merck KgaA, is extending by two years its 10-year R&D cooperation with San Raffaele University & Research Hospital for Research in Milan focusing on neurodegenerative diseases.

The partners are aiming at the development of pre-clinical and clinical research projects with a focus on developing innovative therapies against serious and disabling neurological diseases such as multiple sclerosis affecting young adults in particular.

San Raffaele University & Research Hospital are providing know-how and laboratories to develop new therapies and to evaluate the effectiveness of the molecules developed by Merck Serono.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read